Dr. Juliana Blum Joins BioAesthetics as CEO
BioAesthetics has appointed Dr. Juliana Blum as its new Chief Executive Officer, effective August 12, 2024. Dr. Blum, co-founder and former EVP of Corporate Development at Humacyte (NASDAQ: HUMA), brings 20 years of experience in biotech development and commercialization. Her expertise includes global regulatory affairs, CMC development, and manufacturing scale-up.
BioAesthetics, a biotechnology company focused on biomaterials advancements, is developing the NACgraft™ biologic matrix, an acellular tissue graft for nipple regeneration in breast reconstruction patients. The company is also working on a drug-eluting graft technology for soft tissue reconstruction. Dr. Blum's appointment is seen as a strategic move to guide the company's products towards clinical trials and commercialization.
BioAesthetics ha nominato Dr. Juliana Blum come nuovo Amministratore Delegato, con effetto dal 12 agosto 2024. La Dr. Blum, co-fondatrice ed ex EVP dello Sviluppo Aziendale presso Humacyte (NASDAQ: HUMA), porta con sé 20 anni di esperienza nello sviluppo e commercializatione della biotecnologia. La sua expertise comprende affari regolatori globali, sviluppo CMC e scalabilità della produzione.
BioAesthetics, un'azienda biotech concentrata sui progressi nei biomateriali, sta sviluppando il NACgraft™ biologic matrix, un innesto tessutale acellulare per la rigenerazione del capezzolo nei pazienti di ricostruzione mammaria. L'azienda sta anche lavorando su una tecnologia di innesto a rilascio di farmaci per la ricostruzione dei tessuti molli. La nomina della Dr. Blum è vista come una mossa strategica per guidare i prodotti dell'azienda verso le sperimentazioni cliniche e la commercializatione.
BioAesthetics ha nombrado a Dr. Juliana Blum como su nueva Directora Ejecutiva, con efecto a partir del 12 de agosto de 2024. La Dra. Blum, cofundadora y ex EVP de Desarrollo Corporativo en Humacyte (NASDAQ: HUMA), aporta 20 años de experiencia en desarrollo y comercialización de biotecnología. Su experiencia incluye asuntos regulatorios globales, desarrollo CMC y escalamiento de manufactura.
BioAesthetics, una empresa de biotecnología enfocada en los avances en biomateriales, está desarrollando la NACgraft™ biologic matrix, un injerto de tejido acelular para la regeneración del pezón en pacientes de reconstrucción mamaria. La empresa también está trabajando en una tecnología de injerto liberador de fármacos para la reconstrucción de tejidos blandos. Se considera que el nombramiento de la Dra. Blum es un movimiento estratégico para guiar los productos de la empresa hacia ensayos clínicos y comercialización.
BioAesthetics는 Dr. Juliana Blum을 새로운 최고 경영자로 임명하였으며, 이는 2024년 8월 12일부터 효력이 발생합니다. Blum 박사는 Humacyte (NASDAQ: HUMA)의 공동 창립자이자 전 기업 개발 EVP로서 생명공학 개발 및 상용화 분야에서 20년의 경험을 갖추고 있습니다. 그녀의 전문 분야는 글로벌 규제 업무, CMC 개발 및 제조 규모 확대입니다.
BioAesthetics는 생체 재료 발전에 중점을 둔 생명공학 회사로, 유방 재건 환자를 위한 유두 재생을 위한 세포 없는 조직 이식인 NACgraft™ biologic matrix를 개발하고 있습니다. 이 회사는 또한 연조직 재건을 위한 약물 방출 이식 기술에 대해 작업하고 있습니다. Blum 박사의 임명은 회사의 제품을 임상 시험과 상용화로 안내하기 위한 전략적 조치로 여겨집니다.
BioAesthetics a nommé Dr. Juliana Blum comme nouvelle Directrice Générale, à compter du 12 août 2024. La Dr. Blum, co-fondatrice et ancienne EVP du développement des affaires chez Humacyte (NASDAQ: HUMA), apporte 20 ans d'expérience dans le développement et la commercialisation de la biotechnologie. Son expertise inclut les affaires réglementaires mondiales, le développement CMC et la montée en échelle de la fabrication.
BioAesthetics, une entreprise de biotechnologie axée sur les avancées des biomatériaux, développe la NACgraft™ biologic matrix, un greffon tissulaire acellulaire pour la régénération des mamelons chez les patientes subissant une reconstruction mammaire. L'entreprise travaille également sur une technologie de greffon à libération de médicament pour la reconstruction des tissus mous. La nomination de la Dr. Blum est considérée comme un mouvement stratégique pour orienter les produits de l'entreprise vers des essais cliniques et la commercialisation.
BioAesthetics hat Dr. Juliana Blum zur neuen Geschäftsführerin ernannt, mit Wirkung zum 12. August 2024. Dr. Blum, Mitgründerin und ehemalige EVP für Unternehmensentwicklung bei Humacyte (NASDAQ: HUMA), bringt 20 Jahre Erfahrung in der Entwicklung und Vermarktung von Biotechnologie mit. Ihre Fachkenntnisse umfassen globale Regulierungsangelegenheiten, CMC-Entwicklung und Produktionsausweitung.
BioAesthetics, ein Biotechnologieunternehmen, das sich auf Fortschritte in Biomaterialien konzentriert, entwickelt die NACgraft™ biologic matrix, ein acelluläres Gewebeimplantat zur Wiederherstellung der Brustwarze bei Brustrekonstruktionspatienten. Das Unternehmen arbeitet auch an einer medikamentenfreisetzenden Implantattechnologie zur Rekonstruktion vonWeichgewebe. Die Ernennung von Dr. Blum wird als strategischer Schritt angesehen, um die Produkte des Unternehmens in Richtung klinischer Studien und Vermarktung zu lenken.
- Appointment of experienced biotech executive Dr. Juliana Blum as new CEO
- Dr. Blum's 20 years of experience in biotech development and commercialization
- Progress of NACgraft™ biologic matrix towards clinical trials
- Development of drug-eluting graft technology for soft tissue reconstruction
- None.
Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO of Toragen, Inc. said, “This is an important milestone for BioAesthetics. During the development of every successful biotech company, there comes a time when the founding CEO transitions to a different role and a new CEO with different skill sets is needed for product advancement and commercialization. Dr. Blum’s experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics.”
Dr. Blum joins BioAesthetics following her 20 years spent as Co-founder and EVP of Corporate Development at Humacyte (NASDAQ: HUMA). During that time, she led the development, management, and execution of the company’s novel, commercial scale vascular bioengineering platform, eventually transitioning the start up to a public company. Her experiences and leadership focuses on a broad range of research and development activities through pre-commercialization functions, including global regulatory affairs, CMC development and manufacturing scale up, corporate development activities, integration of key partnerships and alliances, and building a corporate brand and presence around a disruptive technology. Since transitioning out of Humacyte at the end of 2022, she has served as an executive strategist for entrepreneurial biotechnology organizations as an Entrepreneur in Residence at the North Carolina Biotechnology Center, advancing innovations, setting strategic visions and translating research concepts into viable commercial product opportunities in the regenerative medicine and biotherapeutics space.
“I am thrilled to join the BioAesthetics team at this stage of the company, working to advance its next gen drug-eluting graft technology for soft tissue reconstruction towards the clinic,” said Dr. Blum. “The team has done a phenomenal job generating robust pre-clinical data on its drug-eluting graft platform across several indications and continues to evaluate its acellular nipple graft for breast reconstruction, the NACgraft, in the clinic. There is a strong foundation for future growth and innovation around this novel platform that I look forward to leading.”
“Dr. Blum has a proven reputation for developing and managing partnerships and key business relationships critical for organizational growth and portfolio development. She has direct experience leading a company from early-stage discovery through planning a commercial launch for an approved product. This experience is critical for the future growth of BioAesthetics,” said Joseph Nixon, MBA, Director of BioAesthetics and CFO of Locus Biosciences, Inc.
About BioAesthetics:
BioAesthetics Corporation is a biotechnology company focused on transforming lives through advancements in biomaterials. Its first product is an acellular tissue graft for regenerating the nipple (NACgraft™ biologic matrix) for breast cancer patients who are undergoing breast reconstruction. NACgraft is FDA-registered and currently being investigated in clinical studies. In addition, it has a product pipeline focused on acellular regenerative grafts for advanced wound and reconstructive care. BioAesthetics was founded as a spin-out of Tulane University in
For more information on BioAesthetics, visit https://bio-aesthetics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826909991/en/
Source: BioAesthetics Corporation
FAQ
When will Dr. Juliana Blum start as CEO of BioAesthetics?
What is BioAesthetics' main product in development?
What is Dr. Juliana Blum's previous experience in the biotech industry?
What new technology is BioAesthetics working on besides the NACgraft?
